These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 6892713

  • 1. Triiodothyronine suppression tests and TSH-releasing hormone tests before and after I- 131 therapy for Graves' disease.
    Tamai H, Nakagawa T, Takahashi H, Ohsako N, Fukino O, Shinzato R, Suematsu H, Matsuzuka F, Kuma K, Nagataki S.
    J Nucl Med; 1980 Mar; 21(3):240-5. PubMed ID: 6892713
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Changes in serum TSH and T4 after T3 suppression tests in patients treated for hyperthyroidism due to Graves' disease.
    Suematsu H, Tamai H, Esaki M, Kurokawa N, Aoki H, Matsuzuka F, Miyauchi A, Kuma K.
    J Clin Endocrinol Metab; 1977 Nov; 45(5):1013-8. PubMed ID: 579181
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 Gray in Graves' disease].
    Pfeilschifter J, Elser H, Haufe S, Ziegler R, Georgi P.
    Nuklearmedizin; 1997 Apr; 36(3):81-6. PubMed ID: 9162906
    [Abstract] [Full Text] [Related]

  • 7. Thyroid-stimulating immunoglobulins and the control of thyroid function.
    Clague R, Mukhtar ED, Pyle GA, Nutt J, Clark F, Scott M, Evered D, Smith BR, Hall R.
    J Clin Endocrinol Metab; 1976 Sep; 43(3):550-6. PubMed ID: 821961
    [Abstract] [Full Text] [Related]

  • 8. [Serum free thyroxine after 131I therapy for Graves' disease (author's transl)].
    Saito S, Sakurada T, Fukazawa H, Yoshida K, Kaise N, Kitaoka H, Yamamoto M, Kaise K.
    Kaku Igaku; 1981 Dec; 18(10):1421-4. PubMed ID: 6896222
    [No Abstract] [Full Text] [Related]

  • 9. Thyroid gland suppressibility in patients treated with radioiodine for diffuse toxic goiter.
    Burgos FL, Micames C, Rivera JV.
    Bol Asoc Med P R; 1983 Apr; 75(4):173-5. PubMed ID: 6575791
    [No Abstract] [Full Text] [Related]

  • 10. Unresponsiveness to thyrotropin-releasing hormone (TRH) in treated Graves' hyperthyroidism and in euthyroid Graves' disease.
    Clifton-Bligh P, Silverstein GE, Burke G.
    J Clin Endocrinol Metab; 1974 Apr; 38(4):531-8. PubMed ID: 4206830
    [No Abstract] [Full Text] [Related]

  • 11. [Evaluation of T3 suppression and TRH stimulation tests in the diagnosis of ophthalmic Graves' disease].
    Tao Y, Song GX.
    Zhonghua Yi Xue Za Zhi; 1987 Dec; 67(12):665-7. PubMed ID: 3130158
    [No Abstract] [Full Text] [Related]

  • 12. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
    Escobar Jiménez F, Luna López V, Fernández Soto ML, Quezada Charneco M, Glinoer D.
    Med Clin (Barc); 1998 Sep 05; 111(6):205-10. PubMed ID: 9789225
    [Abstract] [Full Text] [Related]

  • 13. [Experience with the thyrotropin releasing hormone (TRH) test in the diagnosis of Graves' ophthalmopathy].
    Otter R, Wiersinga WM, Peeters HF, Bleeker GM, Touber JL.
    Ned Tijdschr Geneeskd; 1982 Nov 27; 126(48):2189-93. PubMed ID: 6817147
    [No Abstract] [Full Text] [Related]

  • 14. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M, Moka D, Reinholz U, Schmidt M, Schomäcker K, Schicha H, Wellner U.
    Nuklearmedizin; 2007 Nov 27; 46(3):77-84. PubMed ID: 17549318
    [Abstract] [Full Text] [Related]

  • 15. Thyrotrophin response to thyrotrophin-releasing hormone in ophthalmic Graves' disease: correlation with other aspects of thyroid function, thyroid suppressibility and activity of eye signs.
    Ormston BJ, Alexander L, Evered DC, Clark F, Bird T, Appleton D, Hall R.
    Clin Endocrinol (Oxf); 1973 Oct 27; 2(4):369-76. PubMed ID: 4128973
    [No Abstract] [Full Text] [Related]

  • 16. Normal serum triiodothyronine concentration and the lack of TSH response to TRH in patients with euthyroid Graves' disease.
    Shimizu T, Shishiba Y.
    Endocrinol Jpn; 1973 Oct 27; 20(5):527-8. PubMed ID: 4209648
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The diagnostic value of the TRH test in thyroid disease].
    Mejer J, Lindholm J.
    Ugeskr Laeger; 1974 Nov 04; 136(45):2519-22. PubMed ID: 4138058
    [No Abstract] [Full Text] [Related]

  • 19. Five years' experience with iodine-125 therapy of Graves' disease.
    Weidinger P, Johnson PM, Werner SC.
    Lancet; 1974 Jul 13; 2(7872):74-7. PubMed ID: 4136737
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.